NVision announced a $55 million Series B financing round as the company expands from quantum sensing into quantum computing, with the goal of accelerating the discovery and validation of new therapies. The funding round was anchored by Abbott and also included a $17 million venture loan from the European Investment Bank. Other investors participating in the round included Playground Global, Matterwave Ventures, and Entrée Capital. The new financing brings NVision’s total capital raised to $120 million.
NVision’s quantum-enhanced sensing platform, POLARIS, leverages quantum technology to amplify MRI signals from sugar-based imaging agents, enabling real-time metabolic measurements with standard MRI systems. The platform is designed to help researchers assess treatment response within hours or days based on disease biology rather than waiting months for conventional imaging methods to reveal morphological changes.
The company is now extending the molecular quantum approach behind POLARIS into quantum computing. During the development of its MRI signal enhancement technology, NVision discovered a new class of organic molecule-based qubits. The company believes these qubits can support a new quantum-driven approach to drug development by enabling the design of more effective drug candidates while POLARIS rapidly validates them in biological environments.
NVision’s vision is to create a unified “compute and validate” system that combines quantum computing for drug design with quantum sensing for real-world therapeutic validation.
POLARIS systems are already being installed at leading cancer centers around the world, with deployments expected at approximately 20 centers across the U.S., Europe, and Asia by the end of the year. Sites include Memorial Sloan Kettering Cancer Center, University of Cambridge, and Technical University of Munich.
The company also introduced its quantum computing platform known as Photonic Integrated Quantum Circuits, or PIQC, pronounced “Pixie.” The platform uses single photon-emitting organic molecules integrated as thin organic layers onto photonic chips, creating a scalable path toward quantum computers built with semiconductor manufacturing technologies.
Sella Brosh, CEO and Co-Founder of NVision, explained that the company sees quantum computing generating a wave of drug hypotheses for diseases that remain difficult to treat today. Brosh added that POLARIS is intended to rapidly validate those hypotheses in vivo, helping close the loop between drug design and biological reality.
Playground Global General Partner Peter Barrett said NVision is changing how cancer is diagnosed and treated by making disease biology visible in new ways. Barrett added that the company’s molecular quantum capabilities now enable both the design and testing of therapies, creating what he described as a new category in quantum health.
Abbott joined the financing round as the sole strategic investor in diagnostics. The company said it is interested in exploring how NVision’s quantum technologies could be applied across diagnostics, disease monitoring, and clinical decision-making.
The European Investment Bank also highlighted the potential impact of NVision’s technology on healthcare systems and Europe’s innovation ecosystem as part of its support for the company’s next phase of growth.
KEY QUOTES:
“I see a future where quantum computers generate an explosion of drug hypotheses for diseases that are exceptionally difficult to treat today. As we expand our ambition into quantum computing, building on our remarkable new class of organic molecule-based qubits, that future comes closer. But without translational speed, we won’t fully realize those gains. POLARIS is built exactly to address this, enabling rapid in-vivo validation and closing the loop between design and reality.”
Sella Brosh, CEO and Co-Founder, NVision
“NVision is fundamentally changing how we find, diagnose, and treat cancer by making the biology of disease visible in ways that weren’t possible before. That same molecular quantum capability now enables both the design and testing of new therapies – defining a new category in quantum health.”
Peter Barrett, General Partner, Playground Global
“At Abbott, we are constantly exploring technologies that can redefine how we understand and diagnose disease. What stands out to us about NVision is their ability to turn complex quantum science into scalable systems for real-world use. We are particularly interested in how quantum technologies can provide earlier insight into disease biology and new ways to understand complex biological systems and data. The field is still early, and we see this as an opportunity to learn, engage closely, and explore how these capabilities may shape the future of healthcare.”
Peter Karabatsos, Divisional Vice President of New Technology, Abbott
“At the EIB, we support innovation that has the potential to improve people’s lives. NVision shows how cutting-edge research can translate into concrete benefits for patients and healthcare systems alike, while strengthening Europe’s innovation ecosystem. We are pleased to accompany the company in this important phase of growth.”
Nicola Beer, Vice President, European Investment Bank
“Since our initial investment in 2017, NVision has developed into a molecular spin-control powerhouse. NVision is among a tiny elite of companies already selling commercially useful quantum sensing systems at scale today. Expanding downstream metabolic imaging with upstream simulation capabilities will create a unique combination for quantum boosted large scale pharma R&D utility.”
Christian Reitberger, Partner, Matterwave Ventures
“NVision proves that quantum isn’t just about the future. It’s already transforming how we measure and understand biology. Their scalable, clinical-grade sensing platform has the potential to redefine MRI and unlock entirely new biological signals. Now, by bringing quantum computing into healthcare as well, they are building a true one-stop platform for quantum-driven healthcare. This is the kind of company that reshapes industries, and we’re proud to have been with them from day one and as they scale.”
Ran Achituv, Managing Partner, Entrée Capital
